Etanercept biosimilar to hit the market

Etanercept biosimilar Brenzys should be available in Australia by early 2017, its maker MSD has said.

The drug was approved by the TGA earlier this year for the treatment of rheumatoid arthritis, spondyloarthritis, psoriatic arthritis and psoriasis, and is currently the subject of a PBAC submission for PBS listing.

“Pending education of healthcare professionals and successful